Skip to main content

Table 1 Percentage of interfering blood required to alter Percepta GSC call

From: Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules

Pre-Test Risk

Post-Test Risk

Low Malignant Blood

High Malignant Blood

Low

Very Low

< 28%

< 25%

Low

> 28%

> 25%

Intermediate

Low

< 20%

< 11%

Intermediate

> 20%

11–97%

High

No call change

> 97%

High

Very High

No call change

No call change